Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
AffordableInnovation
Innovate | Collaborate | Accelerate
www.jubilantbiosys.com www.jchemsys.com
Our Values
We will carefully select, train and develop our people to be creative, empower them to take decisions, so that they respond to all customers with agility, confidence and teamwork.
We stretch ourselves to be cost effective and efficient in all aspects of our operations and focus on flawless delivery to create and provide the best value to our customers.
By sharing our knowledge and learning from each other and from the markets we serve, we will continue to surprise our customers with innovative solutions.
With utmost care for the environment and safety, we will always strive to excel in the quality of our processes, our products and our services.
Our Promise
Caring, Sharing, Growing
We will, with utmost care for the environment
and society, Continue to enhance value for our
customers by providing innovative products and
economically efficient solutions; and for our
stakeholders through growth, cost effectiveness
and wise investment of resources
Our Vision & Our Values
Our Vision
To be the most admired
global life sciences
company enabling
biopharmaceutical
industry to improve
Human Health.
Jubilant Biosys Ltd & Jubilant Chemsys Ltd are part of the Jubilant LifeSciences providing innovative drug discovery solutions to the global pharmaceutical industry. Also called Jubilant Drug Discovery services (JDDS), is enabled through its locations across India and the USA.
Jubilant offers integrated discovery solutions spanning across Target Identification/Target Validation (TI/TV) to Lead Optimization (LO)/Preclinical candidate (PCC), for multiple therapeutic areas.
With well enabled capabilities in Oncology, Metabolic Disorders, CNS, Pain and Inflammation, Jubilant has rapidly emerged as a leading collaborator for biotechnology and pharmaceutical companies worldwide.
In each of these therapeutic areas, Jubilant has developed in-depth expertise in discovery informatics, medicinal chemistry, structural biology, biology, in-vivo and in-vitro biology and translational sciences.
The discovery team focuses on early stage lead generation across various target classes and uses a wide range of technologies, including high throughput screening, molecular modeling, medicinal chemistry, structural biology and others, to identify novel starting points that are then selectively taken through the preclinical discovery process. This is further augmented by our expertise in Animal Pharmacology with multiple pharmacology and in-vivo models enabled internally to deliver high quality IND ready candidates. Jubilant continues to demonstrate optimal to excellent outcomes to our global pharmaceutical collaborators.
Jubilant Drug Discovery:
• 700+ people working on drug discovery spread across three locations Noida and Bangalore in India and Malvern in the USA.
• Demonstrated outcomes and expertise: ~50 programs leading to preclinical decision outcomes with some leading to successful clinical outcomes across multiple therapeutic areas.
• Exploratory and translational outcomes across target and disease platforms enabling “right shots at the goal”.
• Integrated and robust preclinical and “early stage POC” portfolio management.
Jubilant operates on a customized approach offering innovative solutions across the Drug Discovery value chain to the Biotechnology and Pharmaceutical Industry. To suit each client’s requirements in the best possible manner, we offer flexibility through the following Business Models:
• Full Time Equivalent (FTE) based
• Fee For Service (FFS) based
• Integrated Drug Discovery Programs
• Milestone & Hybrid Models
• Risk Sharing Model
Jubilant collaborates with the world’s leading pharmaceutical and biotech companies, academic institutions and research foundations. Innovative and rigorous science, excellence in execution, and absolute integrity, combined with flexible business models has enabled Jubilant to deliver valuable outcomes in a relatively short period of time. The hallmark of Jubilant’s collaborative model is the creation of value to their partners.
Certified ISO 27001:2005 (By British Standards Institution, India)Ju
bila
nt D
rug
Dis
cove
ry S
ervi
ces
Integrated
Integrated Drug Discovery
• Seamless integration from target validation to candidate selection under one roof • Non-GLP tox capabilities • ~50 integrated
projects enabled • Delivered 3 clinical candidates in last 4 years and 3 more expected in IND enabling efforts • PD and Disease model
expertise • 8-10 validated models/TA • Virtual Pharmacology Lab - funcional service for Pain
Initiated Plans
o Tumors from Cancer patients
o Target / substrate expression
o Cell culture
o Mutation analysis
o Xenograft model with primary human tumor
Expansion Plans
o PoM / Target Engagement Biochemical Biomarkers rodent / human accessible tissue
o Test leads in tumor cell lines for molecular profiling & biomarkers
Already In Place
o Dose to Man Predictions
Small Molecule Design• In silico predictions • Virtual libraries • Structure-based design • Ligand-bound structure generation • Rapid HTS follow up •
Rational Design from competitor molecules to generate novel IP
Target Classes• GPCRs • Kinases • Ion-channels • NHRs • Proteases • Epigenetics • Protein-Protein Interactions
Jubilant demonstrated expertise: Differentiated Enablers
Jubilant Drug Discovery Services (JDDS) Sites: Jubilant Biosys-Bengaluru; Jubilant Chemsys-Noida; Malvern-PA.
Seamless Integration
Drug Discovery Capabilities
TI/TV: Bioinformatics, Target proposal (line-of-sight to IND), Target Validation (siRNA, tool cmpds, expression) Build: Target & pathway
expression in human disease tissue, patient stratification
Lead Optimization & Preclinical Devevlopment: Med / Synth Chem, DMPK, in vivo PD & disease models, scale-up, preformulation, non-
GLP Tox, D2M predictions.
Build: Human pharmacodynamic / target engagement biomarkers.
Hit to Lead: HTS, Structural Biology (protein, X-ray crystallography), Med / Comp Chem, in vitro ADME, in vitro / Cell biology Build: Frag-
ment & Lead Library synthesis, human cells (primary)
Target Identification &Validation
Hit to Lead Generation
Lead Optimization &Preclinical Development
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
• Core of innovation, data management and building customer
confidentiality
• >300 Chemists with +10 years of expertise dedicated
overpowering synthetic challenges of delivery compounds
• Individually tailoring the needs of clients facilitated FTEs to be
delivered ranging from milligrams to kilograms
• Access Controlled Modular Laboratories
• Milestone-based contracts enable you to pay for performance
and not just activity
• Armored with an upfront work plan sanctions the efficacy of
protocol preparation
• Standard terms and conditions simplify and encourage lasting
relationships
Molecular Modeling
Design capabilityTools, Proprietary Tech
Docking studies
Synthetic Organic Chemistry Medicinal Chemistry
Rational Drug Design SAR & SPR Optimization
HTL,LO,PCC
Process Research & Optimization
Design, Development, Process execution
Scale-up, Material supply for pre-clinical/tox studies
Analytical Characterization
Methoddevelopment
Purification
Synthesis of scaffolds, building blocks,intermediates, reference compounds
Library Design and synthesis
Noida Site
• Expanded Synthetic chemistry
• Scale up facility - Tox • Pre-formulation and
formulation development
• Special Expertise • Carbohydrate Chemistry • Nucleoside Chemistry • Focused Libraries
• Expertise • Rational Drug Design • IP Generation • Multi-Dimensional
Optimization (MDO)
• Therapeutic Areas • Oncology • CNS • Metabolic Disorders • Pain and Inflammation
Bangalore Site
Jubilant Chemistry Competence
Discovery EnablersChemistry Services
Quality and Deliverables Intellectual Property Data Storage & IP
• Guarantee the standards most suitable to your needs
• To achieve and accommodate a high standard of protection by upgraded access control panels
Service Highlights
• Ensuring that the consumer rights are inevitable served
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Drug Discovery (Target to IND)
Target Classes• Kinases• GPCRs• NHRs• Ion Channels• Proteases• Transporters• Enzymes
Compound Management System• HTS REMP Sample Management Store
Base and Extension
Assay Technologies• Radiometric SPA/filter binding• Fluorescence/colorimetric • HTRF• Alphascreen • ELISA • Atomic absorption• Patch clamp• FACS
Animal Facilities• Nude mice• Rodents
In vivo Efficacy Models (PK-PD)• Oncology• Diabetes/Obesity• CNS• Pain and Inflammation • Respiratory
Biology Assay Development & Validation• Biochemical assays• Cell Based Assays• Target or Pathway Specific Assays• Phenotypic Assays
Drug Discovery (Target to IND)
Target ID & Validation Lead Op & PCCTarget to Hit Hit to Lead IND
• Biobanking• Tissue Banking• Patient sample analysis• Literature mining• Bioinformatics• siRNA• Tool compounds• Cell and animal models
• Gene cloning• Protein Expression and
Purification• Apo and Ligand bound
structures• Biochemical & Cell based
assay development• Screening• In vitro ADME
• Cell based mechanistic and functional assays
• PK, PK-PD• Efficacy Biomarkers• CYP Inhibition• hERG liability • Acute Tox
• PK-PD• Efficacy in multiple
models• Biomarkers• Multiple species PK• Off-target profiling• Gene Tox• TK, Acute and Chronic
Tox
• Preformulation• Regulatory Tox• IND filing
Enabling Discovery across the value chain
Discovery EnablersBiology
Value Addition
Bio-banking-Biomarker Research
Target Identification and Validation
Enhanced Capabilities
HT - Electrophysiology
High Throughput Screening
Ion Channels; GPCRs; Kinases
hERG e-phys
off - Target Screens
Med.Chem
ADME/PKIn vivo
Tox
HTS e-phys
Assays
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Human Tissue Banking• Alliance with local hospital and institutions • Access to human disease tissue • Translational research capabilities
Discovery EnablersDMPK & Toxicology
Jubilant discovery DMPK offers a broad range of high quality services in the areas of in vitro ADME, in vivo PK/TK and bioanalysis, either as part of integrated programs or as a standalone. With investment in state-of-the-art mass spectrometry (LC-MS/MS, HPLC-UV/PDA), automated high throughput sample preparation, robotics and world class laboratory data management Galileo™ and Watson™ LIMS systems, we are capable to work in medium to high throughput environment. Our animal facilities have been accredited by CPCSEA and support a broad range of in vivo DMPK studies involving rat, mice, genetically modified mice and rabbits. We have collaborated with external partners for conducting the dog and monkey PK life phase and bioanalysis is being done at our Bangalore research centre.
Jubilant has a highly skilled and competent scientific team committed to deliver quality results with quick turnaround time. We work closely with our clients, understand their requirement and are flexible in modifying the assay protocols, report templates to match client’s expectation.
The Animal Facility is registered with “Committee for the Purpose of Control and Supervision of Experiments on Animals” (CPCSEA) and AAALAC accredited.
Discovery Enablers-DMPK & Toxicology
Target to Hit
Assessment of physicochemical & In
vitro ADME properties
• In silico properties• Solubility• Log D• Microsomal stability• CYP inhibition
• Solubility• Log D• Metabolic stability• CYP inhibition• Permeability• Plasma protein binding• In vivo PK (rodent)• Reactive metabolite
Optimization of physicochemical &
druggableproperties
Hit to Lead
• Dose range finding (rodent and non- rodent)
• PK/PD• Tissue distribution• Food effect• Metabolite profiling• Safety profiling• Toxicokinetics• CYP induction• Interspecies scaling
Dose range finding, Safety/Tox assessment,
Interspecies scaling
Candidate selection
• Metabolic stability• DDI, TDI/MBI• Permeability (Caco-2,
MDCK-MDR1)• Plasma protein binding• In vivo PK (rodent)• In vivo PK (non-rodent) • Target tissue exposure• Blood/plasma partioning • IVIVC, Renal/Biliary CL• Mass balance• PK/PD• Met ID (soft spot)• Dose-to-man prediction
Optimization of druggable properties,
IVIVC, PK/PD correlation
Lead to optimized lead/ candidate
identification
DMPK Support Across Discovery Chain
Services
• Bioanalytical method
development and validation
• Metabolite identification
• PK and TK in rodent/non-rodents
• Mass balance studies
• Chiral chromatography
• Cocktail analysis
• Formulation analysis
• Plasma protein binding
• Metabolic stability
• Solubility, LogD
• In vitro DDI studies
• Permeability studies
• Preclinical formulation development
TOXICOLOGY & GENOTOX (Non-GLP)Genotoxicity:• Ames test • Chromosomal Aberration test • Micronucleus test
Toxicology:• Acute toxicity studies in Rats and mice• MTD studies in rat and mice with TK• Dose escalation and range-finding• 4, 7 and 14 day studies in rat and mice with TK
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Jubilant Biosys computational chemistry team excels in drug discovery design efforts in collaboration with medicinal chemistry, structural biology biology and DMPK teams, by conducting molecular modeling studies - pharmacophore and QSAR modeling, protein structure-based drug design, ligand-based drug design, fragment-based drug design, homology modeling, docking & scoring, chemoinformatics analysis and de novo design. The team of 20 scientists extensively utilizes in-house expertise in software development, chemo-curation and structural biology for driving molecular design.
Achievements
• The Jubilant modeling group is actively involved in over twenty integrated drug discovery projects and modeling collaborations.• Molecular modeling and structure-based drug design techniques have been employed in the development of two clinical candidates
(GPCR, kinase targets) and a back up candidate (protease target) for clinical trials.• Jubilant computational chemistry group played a critical role in the design and successful development of multi-kinase inhibitor series for
multiple projects:• Two different, novel and potent lead series of inhibitors for a dual kinase inhibitor program• Two different lead series of novel, potent inhibitors for a triple kinase inhibitor program
Molecular Design Collaborations (MDC)• Jubilant computational chemistry team empowers drug discovery scientists to deploy ready-to-use models and make faster and wiser
decisions:
• Virtual screening• Protein-ligand
interactions• Validated docking
models and scoring• SAR analysis• Selectivity analysis• Activity prediction• Suggestions for synthesis
/ testing
• Template search• Validated homology
models• Sequence analysis• Structural analysis• Comparison of
homologous proteins
• Validated pharmacophore/ 3D-/2D-QSAR models
• Activity prediction• SAR analysis• Selectivity analysis• Cluster analysis• Suggestions for synthesis
/ testing
• Analysis of PDBs• Compare & characterize
binding sites• PDB water analysis• Calculate ligand
properties• Correlate activity &
properties
Docking Homology modeling MiscellaneousPharmacophore/ QSAR
IC50 = x IC50 > x/1000Apo enzyme
Fragment based drug discovery
Discovery EnablersComputational Chemistry
ReportsStructural Biology
Chemistry
Models
Structural Biology
Data
Biology
Chemo Informatics
Bio Informatics Pharmacology
Computational & Informatics
Support
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Jubilant has the most experienced Structural Biology team,
offering integrated and functional services
Integrated Drug Discovery Support:
• Structure Based Drug Design (SBDD)
Functional Services:
• Gene to Structure, Protein to
Structure
• Ligand-bound structures
• Sructure refinement and annotation
• Crystal image annotation
• Low Endotoxin Proteins for
Therapeutics
• Cell Line Generation
Reagents and Cell Line Generation:• Kinases, Carboxylases, Ion channels,
GPCRs, Decarboxylases, Hydrolases, Transcription factors, NHRs, lipases, Synthetases, Reporter gene constructs, CYPs, etc.
Targets for Crystal Structures:• Kinases, Phosphatases, Proteases,
Carboxylases, NHRs, Hydrolases, Decarboxylases, Apoptotic proteins, Transferases, ß-lactamases, Deaminases, Fab, Fab-antigen complexes, epigenetic targets, Interleukins etc.
Cloning• Cloning into various vectors• Codon optimized or non-
codon optimized synthetic genes
• Full length, catalytic domain, chimeras, mutants, etc.
Protein Expression• E. coli system: Various strains,
co-expression• Insect cell system: Sf9, Sf21, Hi5• Mammalian expression system• Co-expression, dual vectors• BIIC system in place
Protein Purification• Various affinity tags: His6,
GST, HA, MBP, FLAG, etc.• Conventional techniques• Refolding from IBs• Purification using AKTAs
Crystallization• Various screening kits• Various seeding techniques• Soaking /co-crystallization
with compounds• Protein-protein complexes
Crystal Image Annotation• Manual annotation of
crystallization images with broad classifications
• Over 40 million images annotated in the past 7 years
• Customized annotation tools• 99.5% scoring accuracy• 24 hour turn-around time
to support clients based in Europe and USA
Data Collection• X-ray diffraction data
collection in house• Resolution range 1.6 - 2.9Å• Molecular weight
10kD - 90kD• ASU containing 1 - 6
molecules
Structure Determination• 20+ different target proteins
in 3+ years• Both known and novel
structures• Capabilities in experimental
phasing (SAD, MAD, etc.)
Ligand Fitting• >150 ligand bound
structures delivered for various target proteins
• Accuracy in ligand fitting using automated software
• Quick evaluation of positives in fragment-based screening
• Mode of binding evaluation to support QSAR/scaffold search
Structure Refinement• Protein-ligand structure
refinement in SBDD projects• Structure solution using MR
for known or similar targets• Structures thoroughly
validated for quality• Fast turnaround time• 4000+ structures on 100+
different target proteins refined in 5+ years
Services
Discovery EnablersStructural Biology
New Initiatives
Antibody Therapeutics
Fragment Based Drug Designing
Gram Quantity
Production from
Mammalian System
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Discovery EnablersPharma IT Services
Jubilant Biosys has a strong IT services division, which is an integral part of the overall service offering of the company.
The IT team comprises of highly skilled professionals from reputed academic institutions and IT companies.
Our IT consultants have vast experience in Life Sciences with emphasis on Discovery R &D, Clinical Research, Manufacturing and Bioinformatics.
The team has expertise in developing various life science products using both Sun and Microsoft’s cutting edge technologies.
We offer following services in various phases of drug discovery:
• Product Engineering Services
• Application Development & Maintenance Services
• Solutions and Discovery Platform Development
Discovery R&D&
Bioinformatics
Life Science
ClinicalResearch
Manufacturing
• Lab Automation• Decision Support System• Research Tools and Applications• Biomarker Research Products• Public Domain Database Integration
• Enterprise Life Science Grid
Development
• Screening Platforms
• Chemistry Solutions
• Workflow Automation for Chemistry,
Structure Biology, HTS, Biology.
• Trial Stat. Orbit - EDC Component of Clinical Suite
• Clinical Knowledge Management Portal
• On-demand SaaS/Cloud data management system
• Data warehouses and Business Intelligence
• Supply Chain Management System
• Laboratory Information
Management System (LIMS)
• Chemical Inventory Management
System
• Analytical Management System
Jubilant Pharmaceutical Expertise
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Biomarker Knowledge Base (BMKB):
• BMKB provides a platform through which clinical study
centers, biomarker screening sites, biobanks and statisticians
can upload, query and export data. The solution is built on
business intelligence tool and can be used in multi therapy
clinical studies.
Screening Solution:
• Developed and customized a next generation assay screening
tool for mid western pharma company.
Sample Tracking LIMS:
• Customizable solution for user definable business process to
manage the sample process workflow system from various
locations spread globally having efficient accession system to
capture sample, gene, patient and services information.
PathArt:
• It is a pathway articulator tool with rich user interface built
on manually curated pathway information & public domain
databases.
Compound Registration System:
• In-house solution to register the compounds with structure
with structure search ability linked with supply chain
management system and analytical reporting system.
Jubilant Advantage
- Experienced IT team with application development
experience in compound management, assay data handling
software
- State-Of-the- Art in-house life sciences testing environment
- One stop shop for end-to-end Healthcare & Life Science
solutions
- Expertise in informatics (Bio & Chemo informatics) -
commercial product development on pathways, biomarkers &
pharmacology (lead identification and optimization)
- Hand-on experience in integration of 3rd party analytical tools
like genespring, spotfire, pathAssist with custom solutions
- Well versed with JChem SDK, ISIS Host/Base, Kectcher, Bingo,
Indigo, JSDraw for chemistry solutions
- Custom workflow automation solutions for Informatics,
Computational Chemistry, Structure Biology, HTS, Biology, In-vivo
Some specific Product Engineering examples are:
GenomicsTarget
IdentificationTarget
Validation
Chemistry
HT Screening
Clinical Development
Development Candidates
Lead Optimization
Chemical Hits
Genomics Tool Development
Informatics Database Design
CDMS Development
CTMS Development
Biology LIMS Development
System Biology Model Development
Biology LIMS Development
Small Molecules Data Analysis
Microarray Data Analysis
Pathway Data Analysis Comparative
Gene AnalysisAssay Data
Analysis
Compound Registration & Management
Pharmacophore Modeling
ELN Design
Assay Data Validation
Homology Modeling
Chemical Tracking &Inventory Management
2D / 3D QSAR Modeling
Chemical Libraries Database
Discovery EnablersPharma IT Services
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Jubilant offers Informatics services, products, customized knowledge platforms, off-the shelf databases and tailor-made Target Knowledge Packages / reports to accelerate Drug Discovery and Development.
AREAS OF EXPERTISE:
Domain expertise in areas as Oncology, CNS, Metabolic Disorders Asthma/COPD, CVD data integration from public domain and custom data bases, building standards and Ontologies, building and interfacing applications for query and analysis.
Tools : Scientific literature, Patents, open domain data sources
Databases : Public domain databases, Jubilant Proprietary databases
Analytics : Software development, 3rd party tool integration, predictive analytics
Team : A highly skilled team of 60+ scientists with extensive scientific domain expertise
• To Identify new Targets and validate targets
• To identify biomolecules in regulatory pathways
• To offer decision support for molecular design
• To explore new indications for existing targets to help in drug repositioning
Pathway Analysis
Biomarker
Target Knowledge Packages
Informatics Enablers for Discovery
Customized Discovery Informatics & Curation Services
Target Selection and Validation
Hit and Lead Identification
Clinical and Health care informatics
Lead Optimization (Pre-Clinical Candidate)
• Genomics tools development• Microarray data analysis• Pathway visualization
tools• Biomarker analysis tools• Homology modeling
tools• Structure search tools
• Assay data analysis• Assay data validation• Compound
Management• Chemical tracking and
Inventory control• Discovery databases• Database Analytics• PK/PD Analytics
• 2D /3D QSAR Modeling tool
• Pharmacophore Modeling
• PK/PD Analytical Tools• Homology Modeling• Structure Refinement,
Annotation • PK / PD correlation
• CTMS Development• EDC & CDMS systems• Biobank Management• Samples management
and tracking• Biomarkers• Tissue Annotation• PV Support and
Analytics
Tech
nolo
gy a
nd
Tool
s Sol
ution
s
• Pathway data curation and analysis• Biomarker knowledge & discovery• Target Knowledge Package• Microarray data analysis• Genomics data analytics• Biology - Drug databases
• Small Molecule databases curation - Kinase, GPCR, Ion Channel, Protease, NHR, Phosphodiesterase, PPIs
• Drug databases• Chemo-Informatics• PK/PD Data Analysis
• Clinical trial intelligence bank
• Adverse events data, Pharmacokinetics
data.• Post Marketing Data
EDC, CDMData
Cur
ation
Ser
vice
Integrated Informatics and Technology Capabilities & Solutions
Drug Discovery and Development Informatics
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Drug Discovery and Development Informatics
NGS data analysis
• Microarray data analysis
• Chip-seq analysis
• Primer design
• Proteomic analysis
Database Products:
• PathArt™ - A Pathway Knowledge base and articulator
• Molsign® - A Biomarker knowledge base and report generator
• ChemBioBase™ - A small molecule database with structure based query engine
Chemistry Biology Clinical Specific Strategy
• Ligands• Assays and specificities• Chemotypes Analysis• SAR landscape• Computational
Opportunities• IP Space Analysis
• Gene and Protein Information
• Expression Information• Population & Disease• Gene Family
Relationships• Reagents• Therapeutic Areas• Pathways & Markers• Transgenic Models• Direct and Indirect
protein interactions Etc.
• Drug specific data• Inhibitor details• KOL• Investigator knowledge• Investigator Site
Knowledge
• Unique Selling Point• Competitive
Intelligence• Druggability
• Key Opinion Leader assessment
• Formularies and payer intelligence
• Clinical biomarkers
• Identifying diagnostic, efficacy, predictive disease-specific
biomarkers
• Pharmcovigilance
Clinical Informatics
Clinical trial intelligence• Scientific, clinical and health economic intelligence• Outputs presented in choice of formats• Services range from discovery to post-launch• Adverse events information• Current awareness• Clinical trial benchmarking
Drug repositioning strategy intelligence• Information on potential drug combinations• Target knowledge gathering• Identification and gathering information of drugs failed
to show efficacy in late stage clinical trials, without safety issues
• Identification of drugs stalled in development for commercial reasons
• Identification of drugs passed the point of patent expiry; or are being explored in new geographical markets
Pathway Analysis• Identification of poteintial drug targets associated with
disease• Explore regulatory mechanisms• To study Protein protein interactions, and small molecule
kinetics• Applications in systems biology, toxicogenomics, and
biomarker studies• Annotation of genes and proteins along with gene
expression profiles
Biomarkers• Data from Expression studies
• Identifying and categorizing potential biomarkers
• Clinical biomarkers
• Information for mutation, polymorphism, chromosomal
aberrations, epigenetic changes, post translational modifications
Clinical Biomarker Database
Gene Annotation Support
• Background• correction• Qspline• Quantile• Variance-Stabilizingtransformation
• Entrez Gene• Swiss prot• unigene id• Cytoband• RefSeq id
• PathART• Molsign• Disease focus
• K Means• Hierarchical• PCA
• Cut-off by M values• T-statistics• Adjust ed p-values
Annotation InterpretationDifferentialgenesNormalization Clustering
Bioinformatics
[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com
Jubilant Drug Discovery Services
• Company Founded in 2000; part of Jubilant Life Sciences
• Employees 700+ employees. Most PhDs have >10 years of US/EU Pharma experience
• Customers Global Top 10, mid-size and virtual pharmaceutical and biotech companies
Global Footprint
Noida, India
Bangalore, India
Malvern, Pennsylvania, USA
Jubilant Biosys Ltd. (Bengaluru)#96, Industrial Suburb,2nd Stage, Yeshwantpur,Bengaluru - 560 022, India.Tel: +91 80 66628400Fax: +91 80 66628333
Jubilant Chemsys Ltd. (Noida)Jubilant Chemsys LimitedB-34. Sector-58Noida – 201301, UP, India.Tel: +91 120 4093300Fax: +91 120 2586776
Jubilant Discovery Services (US)365, Phoenixville Pike,Malvem, PA - 19355, USATel: 610-240-6690 x101Fax: 610-240-8693
[email protected] | www.jubilantbiosys.com | [email protected] | www.jchemsys.com